Abbvie Inc. vs Novavax Inc
ABBV vs NVAX — side-by-side comparison from reported financials. ABBV leads 6, NVAX leads 4 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Novavax Inc
NVAX · Healthcare
$12.73+15.62%Strong
| Metric | ABBV | NVAX |
|---|---|---|
| Price | $276.43 | $12.73 |
| Market cap | $488B | $2.10B |
| Revenue (TTM) | $64.4B | $414M |
| Revenue growth | +1.8% | -17.2% |
| Net margin | 9.8% | -59.9% |
| Free cash flow | $18.2B | -$42.8M |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | +48.2% |
| P/E | 77.4 | 4.8 |
| P/E vs own history (cheap-side %) | 23% | 29% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 283% |
| Altman Z-score | 2.33 | -5.14 |
| CV checks passed | 9 of 11 | 4 of 11 |
| Employees | 57,000 | 749 |
Full résumé-style profiles: ABBV CV · NVAX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.